Announced Wed, 5 Aug, 2026 · 13:51 IST

Q1 FY27 Results: Standalone Net Loss Rs 125.32L, Consolidated PAT up 347% YoY

Revenue DeclinePat NegativePat Growth 25pctResults View source PDF Explain this filing

BALAXI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.7%Reaction day

₹24.00

prior close

₹24.25

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%+0.4% vs market

On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.7

10m

+0.6

15m

+0.6

30m

+1.4

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+1.7+1.3+0.4

Next day

+0.9+1.6-0.8

+2.2+1.7+0.5

+0.5+1.6-1.2

-1.2+1.5-2.7

+0.0+1.8-1.8

+0.0+2.1-2.0

15d

-5.8+3.2-9.0

+0.1+3.7-3.6

-4.8+1.1-5.9

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone revenue fell to Rs 1,558.37L (vs Rs 1,670.82L YoY) with net loss of Rs 125.32L vs profit of Rs 19.49L. Consolidated revenue grew 14% to Rs 8,068.18L; net profit jumped 347% to Rs 129.74L. Board noted commercial production began at Jadcherla pharma plant with 31 products approved; WHO-GMP audit completed with CAPA submitted. Auditors gave unqualified review reports.

Likely market impact

Mixed results - weak standalone, but strong consolidated growth driven by subsidiaries. Plant ramp-up and WHO-GMP certification are key future positives.